A Prospective Multicenter Study on Patients'Satisfaction With Angeliq® Micro in Real Clinical Practice Conducted in Russia

NCT03126773 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1570

Last updated 2021-06-18

No results posted yet for this study

Summary

To evaluate the patients' satisfaction with Angeliq Micro in real clinical practice after 13 cycles of treatment.

Conditions

Interventions

DRUG

BAY86-4891

Drospirenone 0.25 mg + estradiol hemihydrate 0.5 mg (Angeliq Micro, G03FA17).Dosage form is one tablet a day.

Sponsors & Collaborators

Eligibility

Min Age
50 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-02
Primary Completion
2019-11-30
Completion
2020-06-18

Countries

  • Russia

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03126773 on ClinicalTrials.gov